FINEARTS-HF
Phase III study
FINEARTS-HF phase III study in patients with symptomatic heart failure
Finerenone is also being investigated for the treatment of symptomatic heart failure in the randomised, placebo-controlled, 42-month FINEARTS-HF study (N=~5,500)
FINEARTS-HF study objectives
